White Light
Precision Research Compounds for the Modern Laboratory
White Light specializes in high-purity research chemicals for scientific investigation. Their flagship compound, SR-17018, was first described by researchers at the Scripps Research Institute in 2017 and represents a significant tool compound in mu-opioid receptor pharmacology — a G-protein-biased partial agonist with an 80–100 fold selectivity for G-protein signaling over β-arrestin2 recruitment, the pathway associated with classical opioid side effects.
SR-17018 Tablets
G-protein-biased partial MOR agonist (Kᵢ 11 nM) in a convenient 10-count tablet format. 69% oral bioavailability and efficient CNS penetration support flexible study designs.
Biased Ligand Profile
80–100 fold bias factor for G-protein signaling over β-arrestin2 relative to DAMGO. Near-irreversible MOR binding, yet fully reversible by naloxone — consistent with allosteric site interaction.
Research-Grade Quality
Manufactured under controlled conditions with batch-to-batch consistency. Molecular formula C₁₉H₁₈Cl₃N₃O, molar mass 410.72 g·mol⁻¹, log P 4.75.
Why Choose White Light?
- Scripps Research Pedigree — SR-17018 was developed and first published by Laura Bohn and colleagues at the Scripps Research Institute, with the patent filed in 2016.
- High Oral Bioavailability — 69% oral bioavailability with an approximately 6-hour elimination half-life, simplifying pharmacokinetic study designs.
- Defined Receptor Selectivity — Strong MOR selectivity (Kᵢ 11 nM) with minimal delta-opioid receptor activity (Kᵢ >10,000 nM), supporting clean mechanistic studies.
- Atypical Tolerance Profile — Studied for its reduced tolerance development and withdrawal intensity relative to classical MOR agonists — a key area of opioid dependence research.
Frequently Asked Questions
What is SR-17018?
SR-17018 (C₁₉H₁₈Cl₃N₃O) is a synthetic piperidinylbenzimidazolone compound and G-protein-biased partial agonist at the mu-opioid receptor. It was first described in the scientific literature in 2017 by researchers at the Scripps Research Institute and is used as a pharmacological tool compound for studying biased opioid signaling.
What makes SR-17018 pharmacologically distinct?
SR-17018 shows an 80–100 fold bias for G-protein activation over β-arrestin2 recruitment at the MOR, relative to DAMGO. It also exhibits non-competitive, near-irreversible receptor binding that is nevertheless fully reversed by naloxone, a profile not seen in classical orthosteric opioid agonists.
Is SR-17018 approved for human use?
No. SR-17018 is a research chemical that has only been assessed in preclinical research. It has not been formally studied in humans, is not FDA-approved, and its safety profile in humans is unknown. It is sold strictly for laboratory research purposes.
What research areas is SR-17018 relevant to?
SR-17018 is relevant to opioid receptor pharmacology, biased agonism research, tolerance and dependence mechanisms, safety pharmacology (particularly respiratory depression profiling), and opioid discontinuation/withdrawal research across multiple opioid classes.
Explore related collections: Research Chemicals | All Brands